Compare AbbVie Inc (ABBV) vs Allbirds Inc (BIRD) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

BIRD (Smartbird) trades at $3.47, down 9.87% today, amid a complete pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with negative cash flows and widening losses, though revenue decline has slowed. Recent news highlights the strategic rebranding and new CEO appointment, driving volatile price action. Analyst consensus remains cautious with 78.57% hold ratings, reflecting uncertainty around the business transformation.

Outlook is highly speculative given the radical business model shift. The AI pivot offers growth potential but carries execution risks amid persistent losses and negative equity. Investors face significant volatility as the company transitions, with success dependent on securing AI infrastructure contracts and achieving profitability.